Scolaris Content Display Scolaris Content Display

Фокальная лазерная терапия в дополнение к химиотерапии при ретинобластоме

Appendices

Appendix 1. CENTRAL search strategy

#1 MeSH descriptor: [Retinal Neoplasms] explode all trees
#2 retinoblastoma*
#3 retina* near/3 (cancer* or neoplas* or tumor* or tumour* or malignan* or carcinoma* or adenocarcinoma* or sarcoma*)
#4 MeSH descriptor: [Eye Enucleation] explode all trees
#5 enucleat* or envicerat*
#6 (eye* or globe) near/2 (remov* or extract*)
#7 #1 or #2 or #3 or #4 or #5 or #6
#8 MeSH descriptor: [Antineoplastic Agents] explode all trees
#9 MeSH descriptor: [Antineoplastic Combined Chemotherapy Protocols] this term only
#10 MeSH descriptor: [Combined Modality Therapy] explode all trees
#11 chemotherap* or chemoreduct* or chemothermotherap* or chemoprophyla*
#12 MeSH descriptor: [Vincristine] this term only
#13 MeSH descriptor: [Etoposide] this term only
#14 MeSH descriptor: [Carboplatin] this term only
#15 vincristine* or etoposide* or carboplatin*
#16 #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15
#17 MeSH descriptor: [Lasers] explode all trees
#18 MeSH descriptor: [Light Coagulation] this term only
#19 laser*
#20 photocoagulat*
#21 transpupillary near/2 thermotherap*
#22 TTT
#23 #17 or #18 or #19 or #20 or #21 or #22
#24 #7 and #16 and #23

Appendix 2. MEDLINE Ovid search strategy

1. randomized controlled trial.pt.
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1‐7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. exp Retinal Neoplasms/
14. retinoblastoma$.tw.
15. (retina$ adj3 (cancer$ or neoplas$ or tumor$ or tumour$ or malignan$ or carcinoma$ or adenocarcinoma$ or sarcoma$)).tw.
16. Eye Enucleation/
17. (enucleat$ or envicerat$).tw.
18. ((eye$ or globe) adj2 (remov$ or extract$)).tw.
19. or/13‐18
20. exp Antineoplastic Agents/
21. Antineoplastic Combined Chemotherapy Protocols/
22. exp Combined Modality Therapy/
23. (chemotherap$ or chemoreduct$ or chemothermotherap$ or chemoprophyla$).tw.
24. Vincristine/
25. Etoposide/
26. Carboplatin/
27. (vincristine$ or etoposide$ or carboplatin$).tw.
28. or/20‐27
29. exp Lasers/
30. Light Coagulation/
31. laser$.tw.
32. photocoagulat$.tw.
33. (transpupillary adj2 thermotherap$).tw.
34. TTT.tw.
35. or/29‐34
36. 12 and 19 and 28 and 35

The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville 2006.

Appendix 3. Embase Ovid search strategy

1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1‐5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12‐21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25‐28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp eye tumor/
34. retinoblastoma$.tw.
35. (retina$ adj3 (cancer$ or neoplas$ or tumor$ or tumour$ or malignan$ or carcinoma$ or adenocarcinoma$ or sarcoma$)).tw.
36. Enucleation/
37. (enucleat$ or envicerat$).tw.
38. ((eye$ or globe) adj2 (remov$ or extract$)).tw.
39. or/33‐38
40. exp chemotherapy/
41. antineoplastic agent/
42. multimodality cancer therapy/
43. chemoprophylaxis/
44. (chemotherap$ or chemoreduct$ or chemothermotherap$ or chemoprophyla$).tw.
45. vincristine/
46. etoposide/
47. carboplatin/
48. (vincristine$ or etoposide$ or carboplatin$).tw.
49. or/40‐48
50. exp laser/
51. exp laser coagulation/
52. laser$.tw.
53. photocoagulat$.tw.
54. (transpupillary adj2 thermotherap$).tw.
55. TTT.tw.
56. or/50‐55
57. 39 and 49 and 56
58. 32 and 57

Appendix 4. LILACS search strategy

retinoblastoma or enucleat$ or evicerat$ or retinal cancer$ or retinal neoplasm$ or retinal tumor$ or retinal tumour$ or retinal malignan$ or retinal carcinoma$ or retinal adenocarcinoma$ or retinal sarcoma and chemotherapy or antineoplastic or chemoreduction or chemothermotherapy or chemoprophylaxis or vincristine or etoposide or carboplatin and laser$ or photocoagulat$ or coagulat$ or thermotherap$

Appendix 5. ISRCTN search strategy

(retinoblastoma OR enucleation OR evicerate OR retinal cancer OR retinal neoplasm OR retinal tumor OR retinal tumour OR retinal malignant OR retinal carcinoma OR retinal adenocarcinoma OR retinal sarcoma) AND (chemotherapy OR antineoplastic OR chemoreduction OR chemothermotherapy OR chemoprophylaxis OR vincristine OR etoposide OR carboplatin)

Appendix 6. ClinicalTrials.gov search strategy

(retinoblastoma OR enucleation OR evicerate OR retinal cancer OR retinal neoplasm OR retinal tumor OR retinal tumour OR retinal malignant OR retinal carcinoma OR retinal adenocarcinoma OR retinal sarcoma) AND (chemotherapy OR antineoplastic OR chemoreduction OR chemothermotherapy OR chemoprophylaxis OR vincristine OR etoposide OR carboplatin)

Appendix 7. WHO ICTRP search strategy

(retinoblastoma OR enucleation OR evicerate OR retinal cancer OR retinal neoplasm OR retinal tumor OR retinal tumour OR retinal malignan OR retinal carcinoma OR retinal adenocarcinoma OR retinal sarcoma) = CONDITION AND (chemotherapy OR antineoplastic OR chemoreduction OR chemothermotherapy OR chemoprophylaxis OR vincristine OR etoposide OR carboplatin) = INTERVENTION

Appendix 8. Data on study characteristics

Mandatory items

Optional items

Methods

Study design

  • Parallel‐group RCT i.e. people randomised to treatment

  • Within‐person RCT i.e. eyes randomised to treatment

  • Cluster‐RCT i.e. communities randomised to treatment

  • Cross‐over RCT

  • Other, specify

Exclusions after randomisation

Losses to follow‐up

Number randomised/analysed

How were missing data handled? e.g. available‐case analysis, imputation methods

Reported power calculation (Y/N), if yes, sample size and power

Unusual study design/issues

Eyes or unit of randomisation/unit of analysis

  • One eye included in the study; specify how the eye was selected

  • Two eyes included in the study, both eyes received same treatment; briefly specify how analysed (best/worst/average/both and adjusted for within person correlation/both and not adjusted for within person correlation) and specify if a mixture of 1 eye and 2 eyes

  • Two eyes included in study, eyes received different treatments, specify if correct pair‐matched analysis was done

Participants

Country

Setting

Ethnic group

Equivalence of baseline characteristics (Y/N)

Total number of participants

This information should be collected for total study population recruited into the study. If the study only reports these data for the participants who were followed up only, please indicate.

Number (%) of men and women

Average age and age range

Inclusion criteria

Exclusion criteria

Interventions

Intervention (N = )

Comparator (N = )

(See MECIR 65 and 70)

  • Number of people randomised to this group

  • Drug (or intervention) name

  • Dose

  • Frequency

  • Route of administration

Outcomes

Primary and secondary outcomes as defined in study reports

(See MECIR R70)

List outcomes

Adverse events reported (Y/N)

Length of follow‐up and intervals at which outcomes assessed

Planned/actual length of follow‐up

Notes

Date conducted

Specify dates of recruitment of participants month/year (mm/yr) to mm/yr

Full study name: (if applicable)

Reported subgroup analyses (Y/N)

Were trial investigators contacted?

Sources of funding

Declarations of interest

(See MECIR 69)

Abbreviations
MECIR: Methodological Expectations of Cochrane Intervention Reviews; RCT: randomised controlled trial

Study flow diagram
Figures and Tables -
Figure 1

Study flow diagram